chronic kidney disease

Pollock, C., James, G., Sanchez, J. J. G., Carrero, J. J., Arnold, M., Lam, C. S. P., et al. (2022). Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. Clin Kidney J, 15, 2124-2134.
Habte-Asres, H. H., Murrells, T., Nitsch, D., Wheeler, D. C., & Forbes, A. (2022). Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: Retrospective cohort study. Diabetes Res Clin Pract, 193, 110117.
Weldegiorgis, M., & Woodward, M. (2022). Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom. Bmc Nephrol, 23, 312.
James, G., Sanchez, J. J. G., Carrero, J. J., Kumar, S., Pecoits-Filho, R., Heerspink, H. J. L., et al. (2022). Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep, 7, 2059-2070.
Wilkinson, T. J., Miksza, J., Zaccardi, F., Lawson, C., Nixon, A. C., Young, H. M. L., et al. (2022). Associations between frailty trajectories and cardiovascular, renal, and mortality outcomes in chronic kidney disease. J Cachexia Sarcopenia Muscle.
Dashtban, A., Mizani, M. A., Denaxas, S., Nitsch, D., Quint, J., Corbett, R., et al. (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int.
James, G., Kim, J., Mellström, C., Ford, K. L., Jenkins, N. C., Tsang, C., et al. (2022). Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. Clin Kidney J, 15, 758-770.